Drawing First Blood

Drawing First Blood

Two experts to debate controversial topics in hematology and health care.

Plasma or Recombinant Products for Hemophilia?

For the past half-century, plasma products have been the mainstay for the treatment of patients with hemophilia. In the 1950s, hematologists used large volumes...

Teaching Old Drugs New Tricks?

When the U.S. Food and Drug Administration (FDA) approved CPX-351 (a fixed combination of daunorubicin and cytarabine), it appeared that everything old was new...

Anticoagulation During Pregnancy

Because of physiologic changes during pregnancy, the risk of venous thromboembolism (VTE) is approximately five to 10 times higher than during non-pregnancy, and the...

Is MRD Testing Worthwhile in Myeloma?

With the clinically effective treatment regimens now available for myeloma, more patients can achieve deep and sustained responses. The ability to measure minimal residual...

Should Patients With Myelodysplastic Syndromes Undergo Transplant?

For patients with myelodysplastic syndromes (MDS), hematopoietic cell transplantation (HCT) is the only potentially curative option, but the rates of transplant-related morbidity and mortality...

To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable?

Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug...

Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A

Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For...

FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?

Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this...

Optimal Timing of Transplant in Myeloma

New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront...

Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines?

Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these...
Advertisement

Current Issue

May 2018, Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.